IP Library Granted Patent US 11,110,148
Granted Patent B2
US 11,110,148 · App. 15/981,981 · Granted Sep 7, 2021

Silk fibroin materials and use thereof

Inventors: David L. Kaplan (Concord, MA); Rina Sears (Pine Meadow, CT); Gordana Vunjak-Novakovic (New York, NY); Lorenz Meinel (Niestetal, DE)
Assignees: Trustees of Tufts College; Massachusetts Institute of Technology
A61K38/1825A61K38/1841A61K47/42A61L27/227A61L27/26A61L27/3604A61L27/3847A61L27/3852A61L27/3895A61L27/56D01D5/00D01F4/02Y10T428/29
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,110,148
App. No.
15/981,981
Granted
Sep 7, 2021
Kind
B2
Abstract

The present invention provides processes for producing porous silk fibroin scaffold material. The porous silk fibroin scaffold can be used for tissue engineering. The porosity of the silk fibroin scaffolds described herein can be adjusted as to mimic the gradient of densities found in natural tissue. Accordingly, methods for engineering of 3-dimensional tissue, e.g. bone and cartilage, using the silk fibroin scaffold material are also provided.

Claims (16)

1. A three-dimensional body comprising silk fibroin having interconnected pores, wherein the pores have an average diameter between 50 microns and 100 microns, and wherein total porosity of the three-dimensional body is at least 80%.

2. The three-dimensional body of claim 1 , wherein the silk fibroin is in a beta-sheet conformation.

3. The three-dimensional body of claim 1 , wherein the three-dimensional body comprises from 5% (w/v) to 35% (w/v) of the silk fibroin.

4. The three-dimensional body of claim 1 , wherein the porosity is at least 90%.

5. The three-dimensional body of claim 1 , wherein the porosity is at least 95%.

6. The three-dimensional body of claim 1 , wherein the silk fibroin is substantially free of sericin.

7. The three-dimensional body of claim 1 , wherein the three-dimensional body is an article for tissue engineering or tissue guided regeneration application.

8. The three-dimensional body of claim 1 , wherein the three-dimensional body further comprises an additive.

9. The three-dimensional body of claim 7 , wherein the additive is selected from peptides, antibodies, DNA, RNA, modified RNA/protein composites, glycogens or other sugars and alcohols.

10. The three-dimensional body of claim 7 , wherein the additive is a biologically active or pharmaceutically active compound.

11. The three-dimensional body of claim 7 , wherein the additive is an agent that enhances proliferation or differentiation of a cell.

12. The three-dimensional body of claim 7 , wherein the additive is a bone morphogenetic protein, a basic fibroblast growth factor, an epidermal growth factor, a platelet-derived growth factor, an insulin-like growth factor or a transforming growth factor.

13. The three-dimensional body of claim 7 , wherein the additive is selected from the group consisting of collagen, elastin, fibronectin, vitronectin, laminin and proteoglycans.

14. The three-dimensional body of claim 1 , wherein the silk fibroin is selected from the group consisting of silks from silkworms, silks from spiders, silks from genetically engineered cells, silks from transgenic plants and animals, silks from cultured cells, native silk, silk from cloned full or partial sequences of native silk genes, and silk from synthetic genes encoding silk.

15. The three-dimensional body of claim 1 , wherein the three-dimensional body comprises a cell.

16. A three-dimensional silk fibroin body comprising interconnected pores having an average diameter between 50 microns and 100 microns, wherein the porosity is at least 80%, the silk fibroin body further comprising a biodegradable polymer selected from the group consisting of collagens, polylactic acid or its copolymers, polyglycolic acid or its copolymers, polyanhydrides, elastin, glycosaminoglycans, polysaccharides, and any combinations thereof.

Continuity (5)
Continuation 13680570 · Nov 19, 2012
Continuation 12836692 · Jul 15, 2010
Continuation 10541182
Provisional Application 60438393 · Jan 7, 2003
Related Publication 20190008923A1 · Jan 10, 2019